The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart ...

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The growing number of Australians with obesity is causing economic damage but should the taxpayer fund weight-loss drugs?

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold ...